Today, FBR & Co Downgraded Juno Therapeutics Inc (JUNO) to Market Perform

Today, FBR & Co Downgraded Juno Therapeutics Inc (JUNO) to Market Perform

FBR & Co lowered shares of Juno Therapeutics Inc (NASDAQ:JUNO) from an outperform rating to a market perform rating in a research note issued to investors on Wednesday. The firm currently has $30.00 target price on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on JUNO. Maxim Group dropped their price objective on Juno Therapeutics from $80.00 to $50.00 and set a buy rating on the stock in a research note on Friday, August 5th. Standpoint Research began coverage on Juno Therapeutics in a research note on Thursday, August 25th. They issued a buy rating and a $47.00 price objective on the stock. BTIG Research raised Juno Therapeutics from a sell rating to a neutral rating in a research note on Thursday, November 3rd. Zacks Investment Research downgraded Juno Therapeutics from a hold rating to a sell rating in a research note on Wednesday, October 5th. Finally, Vetr downgraded Juno Therapeutics from a strong-buy rating to a buy rating and set a $38.02 price objective on the stock. in a research note on Tuesday, August 16th. Six analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Buy and an average price target of $40.40.

Juno Therapeutics (NASDAQ:JUNO) opened at 22.12 on Wednesday. The company’s 50-day moving average price is $27.32 and its 200 day moving average price is $32.73. The stock’s market capitalization is $2.27 billion. Juno Therapeutics has a 52-week low of $19.41 and a 52-week high of $57.82.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.05. The firm earned $20.80 million during the quarter, compared to the consensus estimate of $10.98 million. During the same quarter in the previous year, the company earned ($0.26) earnings per share. The business’s quarterly revenue was up 1200.0% on a year-over-year basis. On average, equities research analysts anticipate that Juno Therapeutics will post ($2.54) earnings per share for the current year.

In related news, EVP Robert Azelby sold 12,921 shares of Juno Therapeutics stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $24.14, for a total transaction of $311,912.94. Following the completion of the sale, the executive vice president now owns 48,640 shares of the company’s stock, valued at $1,174,169.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Hans Edgar Bishop sold 84,035 shares of Juno Therapeutics stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $30.28, for a total value of $2,544,579.80. Following the sale, the chief executive officer now directly owns 2,518,537 shares of the company’s stock, valued at approximately $76,261,300.36. The disclosure for this sale can be found here.

Hedge funds have recently added to or reduced their stakes in the stock. D.A. Davidson & CO. boosted its stake in Juno Therapeutics by 40.8% in the third quarter. D.A. Davidson & CO. now owns 16,918 shares of the biopharmaceutical company’s stock worth $507,000 after buying an additional 4,900 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Juno Therapeutics by 0.4% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,698 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 98 shares during the last quarter. Credit Suisse AG boosted its stake in Juno Therapeutics by 51.1% in the third quarter. Credit Suisse AG now owns 187,262 shares of the biopharmaceutical company’s stock worth $5,621,000 after buying an additional 63,346 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new stake in Juno Therapeutics during the third quarter worth about $2,401,000. Finally, Bamco Inc. NY boosted its stake in Juno Therapeutics by 340.8% in the third quarter. Bamco Inc. NY now owns 443,107 shares of the biopharmaceutical company’s stock worth $13,298,000 after buying an additional 342,582 shares during the last quarter.

Juno Therapeutics Company Profile

Related posts

Leave a Comment